PMID- 10098638
OWN - NLM
STAT- MEDLINE
DCOM- 19990603
LR  - 20170214
IS  - 0300-9858 (Print)
IS  - 0300-9858 (Linking)
VI  - 36
IP  - 2
DP  - 1999 Mar
TI  - Expression of vascular endothelial growth factor in
      N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat bladder carcinogenesis.
PG  - 111-6
AB  - Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor
      (bFGF) are proteins implicated in tumor-associated microvascular angiogenesis.
      Expressions of VEGF and bFGF in various stages of chemical-induced rat bladder
      carcinogenesis were immunohistochemically investigated. Thirty-two male
      6-week-old Wistar rats were given drinking water containing 0.05%
      N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) for 20 weeks. VEGF and bFGF were not 
      detected in the normal bladder epithelium. In simple hyperplasia, intensive
      expression of VEGF was observed in a few epithelial cells, and the expression of 
      epithelial VEGF became more pronounced in papillary or nodular (PN) hyperplasia
      and papilloma. In carcinoma, heterogeneous expression of VEGF was observed in
      focal tumor cells, intensely expressed in the invading tumor cells.
      Ultrastructurally, carcinoma cells showed VEGF immunoreactivity in the
      cytoplasmic matrix and some rough endoplasmic reticulum, and VEGF-positive and
      -negative carcinoma cells were also clearly defined. High levels of VEGF mRNA
      were observed in the carcinoma. However, bFGF was not detected in the epithelium 
      throughout the carcinogenesis. Increased microvessel counts appeared at simple
      hyperplasia and became more pronounced in PN hyperplasia, papilloma, and
      carcinoma (F-test; P < 0.05). In the carcinoma, the microvessel counts of the
      VEGF-expressing tumor areas were significantly higher than that of the
      non-VEGF-expressing tumor areas (U-test; P < 0.05). The present study suggests
      that upregulation of epithelial VEGF may begin at a quite early stage in
      BBN-induced rat bladder carcinogenesis, but bFGF may not be involved.
FAU - Wakui, S
AU  - Wakui S
AD  - Comparative Toxicology Laboratories, School of Veterinary Medicine, Azabu
      University, Sagamihara, Kanagawa, Japan. wakui@azabu-u.ac.jp
FAU - Furusato, M
AU  - Furusato M
FAU - Sasaki, S
AU  - Sasaki S
FAU - Muto, T
AU  - Muto T
FAU - Takahashi, H
AU  - Takahashi H
FAU - Masaoka, T
AU  - Masaoka T
FAU - Ushigome, S
AU  - Ushigome S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Vet Pathol
JT  - Veterinary pathology
JID - 0312020
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Carcinogens)
RN  - 0 (Endothelial Growth Factors)
RN  - 0 (Lymphokines)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Vascular Endothelial Growth Factors)
RN  - 0 (von Willebrand Factor)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 3817-11-6 (Butylhydroxybutylnitrosamine)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal
MH  - Blotting, Northern/veterinary
MH  - Butylhydroxybutylnitrosamine
MH  - Carcinogens
MH  - Endothelial Growth Factors/genetics/*metabolism
MH  - Fibroblast Growth Factor 2/genetics/metabolism
MH  - *Gene Expression Regulation
MH  - Immunohistochemistry
MH  - Lymphokines/genetics/*metabolism
MH  - Male
MH  - Microscopy, Electron/veterinary
MH  - Neovascularization, Pathologic/veterinary
MH  - Rats
MH  - Rats, Wistar
MH  - Urinary Bladder/immunology/pathology
MH  - Urinary Bladder Neoplasms/blood supply/chemically induced/metabolism/*veterinary
MH  - Vascular Endothelial Growth Factor A
MH  - Vascular Endothelial Growth Factors
MH  - von Willebrand Factor/immunology
EDAT- 1999/03/31 00:00
MHDA- 1999/03/31 00:01
CRDT- 1999/03/31 00:00
PHST- 1999/03/31 00:00 [pubmed]
PHST- 1999/03/31 00:01 [medline]
PHST- 1999/03/31 00:00 [entrez]
AID - 10.1354/vp.36-2-111 [doi]
PST - ppublish
SO  - Vet Pathol. 1999 Mar;36(2):111-6. doi: 10.1354/vp.36-2-111.